DYNT
Dynatronics Corporation0.0432
+0.0032+8.03%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
693.47KP/E (TTM)
-Basic EPS (TTM)
-1.37Dividend Yield
0%Recent Filings
8-K
Chapter 7 bankruptcy filed
Dynatronics and its subsidiaries ceased operations and filed voluntary Chapter 7 bankruptcy petitions on January 9, 2026, after exhausting strategic alternatives. Chapter 7 trustees will liquidate assets, triggering defaults under the Gibraltar loan and preferred stock redemption rights—stayed under bankruptcy law. Directors and executives, including CEO Brian Baker, resigned upon trustee appointment. Operations ended.
8-K
Shareholders re-elect directors, approve comp
Dynatronics shareholders at the December 11, 2025 annual meeting elected R. Scott Ward, Andrew Hulett, and Brian D. Baker as directors until 2026, with over 11.5M votes for each despite minor withholdings. They ratified Tanner LLC as auditors for fiscal 2026 (12.8M for), approved exec comp (11.5M for), and favored triennial say-on-pay votes (11.5M for 3 years). Board will hold exec votes every three years. Continuity locked in.
10-Q
Q1 FY2026 results
Dynatronics posted Q1 FY2026 net sales of $7.0M, down 7.6% y/y from $7.6M, yet narrowed operating loss to $88K from $251K through 18.5% SG&A cuts to $1.8M; gross margin slipped to 24.7% from 26.1%. Net loss shrank to $202K ($0.03/share on 13.0M diluted shares, antidilutive), versus $367K ($0.09/share). Cash climbed to $762K, buoyed by $607K line-of-credit draw to $2.6M (up to $7.5M availability, SOFR+5%), but lender flagged fixed-charge covenant breach on Sep 16. Orthopedic bracing tumbled 16% y/y to $2.8M. Losses persist. Tariff hikes loom.
10-K
FY2025 results
Dynatronics posted FY2025 net sales of $27.4M, down 15.8% y/y from $32.5M, with gross profit slipping to 21.9% from 23.5% amid OEM volume cuts and soft bracing weakness. Operating loss widened slightly to $2.5M while net loss ballooned to $10.9M after $7.1M goodwill and $1.0M intangible impairments. Q4 drove the annual skid, yet cash from operations turned positive at $301K (derived). Line of credit dipped to $2.0M; no buybacks or dividends beyond preferred. Going concern doubts loom. Supply chain disruptions threaten momentum.
10-Q
Q3 FY2025 results
Dynatronics posted Q3 FY2025 net sales of $6.2M, down 19.7% y/y from $7.7M, with gross margin slipping to 17.8% from 23.7% on softer orthopedic bracing demand (down to $2.8M from $4.0M). Operating loss widened to $944K from $572K as sales volume eroded, yet SG&A fell 14.6% to $2.0M on payroll cuts; net loss hit $999K, just beyond operating loss due to $95K interest. Diluted EPS improved to -$0.13 from -$0.17 on 80% more shares from preferred dividends, though antidilutive options excluded. Cash dwindled to $174K with $217K YTD operating cash flow, line of credit at $1.9M under $7.5M facility (SOFR+5%, min fixed charge coverage if availability < $1M). New sublease optimizes space. Tariffs loom large.
DHAI
DIH Holding US, Inc.
0.75+0.16
EMED
Electromedical Technologies, In
0.00+0.00
ENOV
Enovis Corporation
26.07-0.47
MDT
Medtronic plc.
97.72-0.85
OSSFF
EMBLA MEDICAL
5.33+0.00
SNN
Smith & Nephew SNATS, Inc.
32.31+0.08
SNWV
SANUWAVE Health, Inc.
31.46-0.18
SYK
Stryker Corporation
351.69-3.62
XTNT
Xtant Medical Holdings, Inc.
0.73+0.04
ZYXI
Zynex, Inc.
0.34-0.32